| P/E (FY) | — | Sales (TTM) | $268.7M |
| Earnings (TTM) | -$15.0M | ROE | −8.42% |
| Net Margin | −1.89% | ROIC | 9.38% |
| Debt / Equity | 4.77 | TD / EBITDA | 7.85 |
| EPS Growth 3Y | — | Sales Growth 3Y | 45.39% |
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States through its Branded and ImprimisRx segments. ImprimisRx offers ophthalmology-focused compounded medications. The company also provides products including IHEEZO, IOPIDINE, VEVYE, ZERVIATE, MAXITROL, ILEVRO, NEVANAC, BYOOVIZ, and VIGAMOX for various ophthalmic conditions such as surgical anesthesia, inflammation, macular degeneration, and infection.
| Market Cap | $1.47B | Trading Days | 4731 |
| 52W High | 54.85 |
| 52W Low | 28.54 |
| % Off High | −28.31% |
| YTD | −19.76% | 1Y | 12.79% |
| 3Y | 83.31% | 5Y | 328.32% |
| 10Y | 908.15% | Since incept. (ann.) | 2.66% |
Branded 72% · Imprimis Rx 28%
| Ann. Volatility (1Y) | 67.70% | Ann. Volatility (3Y) | 75.02% |
| Sharpe (1Y) | 0.54 | Sharpe (3Y) | 0.63 |
| Max Drawdown (1Y) | −47.03% | Max Drawdown (3Y) | −63.32% |
| Beta (3Y, vs SPY) | 1.81 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CMPS | COMPASS Pathways plc | $1.46B | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.46B | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.48B | 30.6 |
| XNCR | Xencor Inc | $1.48B | — |
| PRGO | PERRIGO Co plc | $1.43B | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.42B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| SEPN | Septerna, Inc. | $1.53B | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | — |
| MLTX | MoonLake Immunotherapeutics | $1.38B | — |
| INVA | Innoviva, Inc. | $1.61B | 6.6 |
| ABCL | AbCellera Biologics Inc. | $1.62B | — |
